We’ve recently updated our valuation analysis.

Ascletis Pharma Valuation

Is 1672 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1672?

Other financial metrics that can be useful for relative valuation.

1672 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.4x
Enterprise Value/EBITDA-4.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 1672's PS Ratio compare to its peers?

The above table shows the PS ratio for 1672 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.5x
1167 Jacobio Pharmaceuticals Group
21.5x40.1%HK$3.5b
1875 TOT BIOPHARM International
7.1xn/aHK$1.7b
2126 JW (Cayman) Therapeutics
16.6x48.5%HK$1.8b
6628 Transcenta Holding
32.9x52.4%HK$1.6b
1672 Ascletis Pharma
44x59.4%HK$3.9b

Price-To-Sales vs Peers: 1672 is expensive based on its Price-To-Sales Ratio (44x) compared to the peer average (19.5x).


Price to Earnings Ratio vs Industry

How does 1672's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a53.3%
n/an/an/a

Price-To-Sales vs Industry: 1672 is expensive based on its Price-To-Sales Ratio (44x) compared to the Hong Kong Biotechs industry average (21.3x)


Price to Sales Ratio vs Fair Ratio

What is 1672's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1672 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio44x
Fair PS Ratio14.4x

Price-To-Sales vs Fair Ratio: 1672 is expensive based on its Price-To-Sales Ratio (44x) compared to the estimated Fair Price-To-Sales Ratio (14.4x).


Share Price vs Fair Value

What is the Fair Price of 1672 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1672's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1672's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1672 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$3.47
HK$2.92
-15.8%
36.4%HK$4.42HK$2.07n/a3
Nov ’23HK$2.60
HK$2.15
-17.4%
4.4%HK$2.24HK$2.05n/a2
Oct ’23HK$2.75
HK$2.29
-16.8%
0.6%HK$2.30HK$2.27n/a2
Sep ’23HK$3.23
HK$2.34
-27.6%
2.2%HK$2.39HK$2.29n/a2
Aug ’23HK$3.36
HK$2.37
-29.5%
3.6%HK$2.45HK$2.28n/a2
Jul ’23HK$3.79
HK$2.41
-36.5%
0.7%HK$2.42HK$2.39n/a2
Jun ’23HK$3.80
HK$2.41
-36.7%
0.7%HK$2.42HK$2.39n/a2
May ’23HK$4.26
HK$2.41
-43.5%
0.7%HK$2.42HK$2.39n/a2
Apr ’23HK$5.09
HK$2.53
-50.4%
3.1%HK$2.60HK$2.45n/a2
Mar ’23HK$4.58
HK$2.53
-44.8%
2.8%HK$2.60HK$2.46n/a2
Feb ’23HK$3.96
HK$2.53
-36.2%
2.8%HK$2.60HK$2.46n/a2
Jan ’23HK$3.29
HK$2.65
-19.5%
7.5%HK$2.85HK$2.45n/a2
Dec ’22HK$3.13
HK$2.67
-14.6%
6.5%HK$2.85HK$2.50n/a2
Nov ’22HK$2.75
HK$3.24
+17.7%
26.4%HK$4.43HK$2.47HK$2.603
Oct ’22HK$2.65
HK$3.24
+22.1%
26.4%HK$4.43HK$2.47HK$2.753
Sep ’22HK$2.87
HK$3.28
+14.3%
25.0%HK$4.39HK$2.45HK$3.233
Aug ’22HK$2.93
HK$3.73
+27.2%
15.2%HK$4.40HK$3.01HK$3.363
Jul ’22HK$3.53
HK$3.73
+5.6%
15.2%HK$4.40HK$3.01HK$3.793
Jun ’22HK$3.61
HK$3.73
+3.2%
15.2%HK$4.40HK$3.01HK$3.803
May ’22HK$2.96
HK$3.71
+25.4%
15.2%HK$4.38HK$3.00HK$4.263
Apr ’22HK$2.90
HK$3.74
+28.9%
15.3%HK$4.40HK$3.01HK$5.093
Mar ’22HK$3.05
HK$3.74
+22.5%
15.3%HK$4.40HK$3.01HK$4.583
Feb ’22HK$2.93
HK$3.75
+28.1%
16.0%HK$4.47HK$3.00HK$3.963
Jan ’22HK$2.87
HK$3.77
+31.3%
14.0%HK$4.43HK$3.13HK$3.293
Dec ’21HK$2.82
HK$3.84
+36.3%
14.0%HK$4.40HK$3.12HK$3.133
Nov ’21HK$2.79
HK$3.79
+35.8%
16.2%HK$4.50HK$3.00HK$2.753

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies